Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
CNS Drugs
Published in: CNS Drugs 5/2012

01-05-2012 | Current Opinion

Off-Label Use of Atypical Antipsychotics

Cause for Concern?

Authors: Andrew McKean, Erik Monasterio

Published in: CNS Drugs | Issue 5/2012

Login to get access

Abstract

Licensed indications for medicines were designed to regulate the claims that can be made about a medicine by a pharmaceutical company. Off-label prescribing (i.e. prescribing a drug for an indication outside of that for which it is licensed) is legal and an integral part of medical practice. In psychiatry, off-label prescribing is common and gives clinicians scope to treat patients who are refractory to standard therapy or where there is no licensed medication for an indication. However, efficacy or safety of such off-label use may not be established.
There is a growing list of licensed indications for atypical antipsychotics (AAP) beyond schizophrenia and bipolar affective disorder, and also more evidence for other indications where pharmaceutical companies have not obtained a license. Pharmaceutical companies have promoted AAPs for off-label indications to increase sales and consequently have been fined by the US FDA for this.
Since the 1990s, AAP use has expanded considerably, for example, the off-label use of quetiapine alone accounted for an estimated 17% of the AAP spend in New Zealand in 2010. There are a number of potential problems with the expanded use of AAPs outside of schizophrenia and related psychoses. A larger population will be exposed to their adverse effects, which include weight gain, type 2 diabetes mellitus, sudden cardiac death and increased mortality rates in the elderly with dementia. There are also concerns with the abuse of these agents, in particular quetiapine.
Given that an increasing percentage of the population is being treated with these agents, off-label prescribing of AAPs is a cause for concern; they have a propensity to cause significant side effects and their efficacy and long-term safety for most off-label indications remains largely unknown, and therefore the risks and benefits of their use should be carefully weighed up prior to prescribing these agents off-label.
Literature
1.
Healy D, Nutt D. Prescriptions, licenses and evidence. Psychiatr Bull 1998; 22: 680–4CrossRef
2.
Avorn J, Kesselheim A. A hemorrhage of off-label use. Ann Intern Med 2011; 154(8): 566–7PubMed
3.
Radley DC, Finkelstein MD, Randall S, et al. Off-label prescribing among office-based physicians. Arch Int Med 2006; 166: 1021–6CrossRef
4.
Pickar D, Vinik J, Bartko J. Pharmacotherapy of schizophrenic patients: preponderance of off-label drug use. PLoS 2008;3: 9 e150
5.
Chakos MH, Glick ID, Miller AL, et al. Baseline use of concomitant psychotropic medications to treat schizophrenia in the CATIE trial. Psychiatr Serv 2006; 57: 1094–101PubMedCrossRef
6.
Leslie D, Mohamed S, Rosenheck R. Off label use of antipsychotic medications in the department of Veterans Affairs health care system. Psychiatr Serv 2009; 60(9): 1175–81PubMedCrossRef
7.
Haw C, Stubbs J. A survey of the off-label-use of mood stabilizers in a large psychiatric hospital. J Psycho-pharmacol 2005; 19: 402–7CrossRef
8.
Martin-Latry K, Ricard C, Verdoux H. A one-day survey of characteristics of off-label hospital prescription of psycho-tropic drugs. Pharmacopsychiatry 2007; 40(3): 116–20PubMedCrossRef
9.
Hampton T. Experts weigh in on promotion, prescription of off-label drugs. JAMA 2007; 297(7): 683–4PubMedCrossRef
10.
Kuehn B. FDA panel issues mixed decision on quetiapine in depression and anxiety. JAMA 2009; 301(20): 2081–2PubMedCrossRef
11.
12.
13.
14.
Maher A, Maglione M, Bagley S, et al. Efficacy and comparative effectiveness of atypical antipsychotic medications for off label uses in adults: a systematic review and meta-analysis. JAMA 2011; 306(12): 1359–69PubMedCrossRef
15.
16.
Kesselheim A, Mello M, Studdert D. Strategies and practices in off-label marketing of pharmaceuticals: a retrospective analysis of whistleblower complaints. PLoS Med 2011;8(4): e1000431PubMedCrossRef
17.
18.
Hopkins Tanne J. AstraZeneca pays $520 m fine for off label marketing. BMJ 2010; 340: c2380CrossRef
19.
Kmietowicz Z. Eli Lilly pays record $1.4bn for promoting off-label use of olanzapine. BMJ 2009; 338: b217PubMedCrossRef
20.
Stafford R. Regulating off-label drug use: rethinking the role of the FDA. N Engl J Med 2008; 358(14): 1427–9PubMedCrossRef
21.
Kesselheim AS, Studdert DM, Mello MM. Whistle-blowers’ experiences in fraud litigations against pharmaceutical companies. N Engl J Med 2010; 362: 1832–9PubMedCrossRef
22.
23.
Tanne JH. FDA oversight of drug company promotion of off label use is poor, US watchdog says. BMJ 2008; 337: a1163CrossRef
24.
Gagnon MA, Lexchin J. The cost of pushing pills: a new estimate of pharmaceutical promotion expenditures in the United States. PLoS Med 2008; 1(5): 29–33
25.
Crystal S, Olfson M, Huang C, et al. Broadened use of atypical antipsychotics: safety, effectiveness, and policy challenges. Health Affairs 2009; 28(5): w770–81PubMedCrossRef
26.
Ashcroft DM, Frischer M, Lockett S, et al. Variations in prescribing atypical antipsychotic drugs in primary care: cross-sectional study. Pharmacoepidemiol Drug Saf 2002; 11: 285–9PubMedCrossRef
27.
Alexander GC, Gallagher SA, Mascola A, et al. Increasing off-label use of antipsychotic medications in the United States, 1995–2008. Pharmacoepidemiol Drug Saf 2011; 20(2): 177–84PubMedCrossRef
28.
Kalverdijk LJ, Tobi H, van den Berg PB, et al. Use of antipsychotic drugs among Dutch youths between 1997 and 2005. Psychiatr Serv 2008; 59: 554–60PubMedCrossRef
29.
30.
Kuehn B. Questionable antipsychotic prescribing remains common despite serious risks. JAMA 2010; 303(16): 1582–4PubMedCrossRef
31.
Monasterio E, McKean A. Off-label use of atypical antipsychotic medications in Canterbury, New Zealand. N Z Med J 2011; 124(1336): 24–9PubMed
32.
Sankaranarayanan J, Puumala S. Antipsychotic use at adult ambulatory care visits by patients with mental health disorders in the United States, 1996–2003: national estimates and associated factors. Clin Ther 2007; 29(4): 723–41PubMedCrossRef
33.
Comer J, Mojtabai R, Olfson M. National trends in the antipsychotic treatment of psychiatric outpatients with anxiety disorders. Am J Psychiatry 2011; 168: 1057–65PubMedCrossRef
34.
Kamble P, Sherer J, Chen H, et al. Off-label use of second generation antipsychotic agents among elderly nursing home residents. Psychiatr Serv 2010; 61(2): 130–6PubMedCrossRef
35.
Tiller J, Ames D, Brodaty H, et al. Antipsychotic use in the elderly: what doctors say they do, and what they do. Aust J Ageing 2008; 27(3): 134–42CrossRef
36.
Kales HC, Zivin K, Kim HM, et al. Trends in antipsychotic use in dementia 1999–2007. Arch Gen Psychiatry 2011; 68(2): 190–7PubMedCrossRef
37.
Domino M, Swartz M. Who are the new users of antipsychotic medicines? Psychiatr Serv 2008; 59(5): 507–14PubMedCrossRef
38.
Tiihonen J, Lonnqvist J, Wahlbeck K, et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 2009; 374(9690): 620–7PubMedCrossRef
39.
Trifiro G, Gambassi G, Sen E, et al. Association of community acquired pneumonia with antipsychotic drug use in elderly patients. Ann Intern Med 2010; 152: 418–25PubMed
40.
Pratt N, Roughead E, Ramsay E, et al. Risk of hospitalization for hip fracture and pneumonia associated with anti-psychotic prescribing in the elderly. Drug Saf 2011; 34(7): 567–75PubMedCrossRef
41.
Dorsey E, Rabanni A, Gallagher S, et al. Impact of FDA black box advisory on antipsychotic medication use. Arch Intern Med 2010; 170(1): 96–103PubMedCrossRef
42.
Cates M, Jackson C, Feldman J, et al. Metabolic consequences of using low dose quetiapine for insomnia in psychiatric patients. Community Ment Health J 2009; 45: 251–4PubMedCrossRef
43.
Brecher M, Leong R, Stening G, et al. Quetiapine and long-term weight change: a comprehensive data review of patients with schizophrenia. J Clin Psychiatry 2007; 68(4): 597–603PubMedCrossRef
44.
Kessing L, Thomsen A, Mogensen U, et al. Treatment with antipsychotics and the risk of diabetes in clinical practice. Br J Psychiatry 2010; 197: 266–71PubMedCrossRef
45.
Ray W, Chung C, Murray K, et al. Atypical antipsychotics and the risk of sudden cardiac death. New Engl J Med 2009; 360(3): 225–35PubMedCrossRef
46.
Pierre JM, Shnayder I, Wirshing DA, et al. Intranasal quetiapine abuse [letter]. Am J Psychiatry 2004; 161: 1718PubMedCrossRef
47.
Hussain MZ, Waheed W, Hussain S. Intravenous quetiapine abuse [letter]. Am J Psychiatry 2005; 162: 1755–6PubMedCrossRef
48.
Hanley M, Kenna G. Quetiapine: treatment for substance abuse and drug of abuse. Am J Health Syst Pharm 2008; 65(1): 611–8PubMedCrossRef
49.
Waters BM, Joshi KG. Intravenous quetiapine-cocaine use (‘Q-ball’) [letter]. Am J Psychiatry 2007; 164: 173–4PubMedCrossRef
50.
Metadata
Title
Off-Label Use of Atypical Antipsychotics
Cause for Concern?
Authors
Andrew McKean
Erik Monasterio
Publication date
01-05-2012
Publisher
Springer International Publishing
Published in
CNS Drugs / Issue 5/2012
Print ISSN: 1172-7047
Electronic ISSN: 1179-1934
DOI
https://doi.org/10.2165/11632030-000000000-00000

Other articles of this Issue 5/2012

CNS Drugs 5/2012 Go to the issue

Original Research Article

Randomized Clinical Study of a Histamine H3 Receptor Antagonist for the Treatment of Adults with Attention-Deficit Hyperactivity Disorder

Leading Article

Minocycline

Current Opinion

Taking the Negative View of Current Migraine Treatments

Adis Drug Evaluation

Quetiapine

Review Article

Long-Acting Injectable Antipsychotics for the Maintenance Treatment of Bipolar Disorder